Sugi Predict

Sugi Predict / Compounds / SCHEMBL126548

SCHEMBL126548

SCHEMBL126548

CC(C)(C)CCN1CCOCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ ALDH1A1 P00352 5/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ KEAP1 Q14145 1/20 0.46
▸ SIGMAR1 Q99720 1/20 0.43
▸ OPRM1 P35372 1/20 0.42
▸ OPRD1 P41143 1/20 0.42
▸ CYP2D6 P10635 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ GLA P06280 1/20 0.42
▸ TP53 P04637 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ CYP3A4 P08684 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ HPGD P15428 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ ARG1 P05089 1/20 0.38
▸ ARG2 P78540 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17307169 0.92 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL8282663 0.86 SMN1; SMN2 (0.54) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL15183464 0.86 SMN1; SMN2 (0.41) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL10192038 0.85 SMN1; SMN2 (0.52) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL22017110 0.84 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL20153265 0.84 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL13814225 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL17523770 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL14003747 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E
SCHEMBL17523783 0.83 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1024 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3363788-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2018-08-22 — — EP claimed
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2013-06-27 — — US claimed
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS ARENA PHARMACEUTICALS, INC. 2012-08-23 — — US claimed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 — — US disclosed
US-20240229026-A1 CHIRAL CONTROL WAVE LIFE SCIENCES LTD. (SG) 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 — — US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 — — US disclosed
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS INTELLIKINE LLC 2024-06-27 — — US disclosed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-12016835-B2 Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2024-06-25 — — US disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 — — US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 — — US disclosed
US-20070021428-A1 Immunomodulating heterocyclic compounds AVIDEX LIMITED (GB) 2007-01-25 — — US disclosed
US-7163939-B2 Macrocyclic kinase inhibitors ABBOTT LABORATORIES (US) 2007-01-16 — — US disclosed
US-7160883-B2 Pyrrolo-triazine aniline compounds useful as kinase inhibitors BRISTOL-MYERS-SQUIBB COMPANY (US) 2007-01-09 — — US disclosed
US-7160907-B2 Pleuromutilin derivatives SMITHKLINE BEECHAM P.L.C. (GB) 2007-01-09 — — US disclosed
US-7157582-B2 Selective iGluR5 receptor antagonists ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
WO-2004052851-A1 PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA GLAXO GROUP LIMITED (GB) 2004-06-24 — — WO disclosed
US-4384968-A TREATING GAS STREAM WITH MORPHOLINE OR SERIVATIVE BETZ LABORATORIES, INC. (US) 1983-05-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214766-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885MEN1 1116/4885KMT2A 2962/4885
US-20240209000-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PIK3CA, PIK3CG, PIK3CD SMN1; SMN2 2664/4885MEN1 883/4885KMT2A 2734/4885
US-20240229026-A1 CHIRAL CONTROL RNGTT, POLI, NSUN3 SMN1; SMN2 695/4885MEN1 2026/4885KMT2A 2211/4885
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors AURKA, AURKB, AURKC SMN1; SMN2 4374/4885MEN1 1380/4885KMT2A 622/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 SMN1; SMN2 1943/4885MEN1 142/4885KMT2A 4008/4885
US-20070021428-A1 Immunomodulating heterocyclic compounds CD40, CD40LG, NGFR SMN1; SMN2 4416/4885MEN1 1041/4885KMT2A 2236/4885
US-12016835-B2 Neprilysin inhibitors MME, REN, ACE SMN1; SMN2 1081/4885MEN1 652/4885KMT2A 2270/4885
US-20130165412-A1 CANNABINOID RECEPTOR MODULATORS CNR1, CNR2, TRPV1 SMN1; SMN2 208/4885MEN1 1116/4885KMT2A 2962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.